Study Comparing Daratumumab, Lenalidomide, and Dexamethasone With Lenalidomide and Dexamethasone in Participants With Previously Untreated Multiple Myeloma
- Status
- COMPLETED
- Phase
- PHASE3
Clinical Trials Related to Lenalidomide
Related studies linked through entity extraction aliases.
Romidepsin and Lenalidomide in Treating Patients With Previously Untreated Peripheral T-Cell Lymphoma
- Status
- COMPLETED
- Phase
- PHASE2
Lenalidomide and Obinutuzumab in Treating Patients With Recurrent or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
- Status
- TERMINATED
- Phase
- PHASE2
Study of the Efficacy and Safety of RsqVD Combination Therapy for Patients With Newly Diagnosed Multiple Myeloma
- Status
- COMPLETED
- Phase
- PHASE2
STUDY TO DETERMINE THE EFFICACY AND SAFETY OF STANDARD SCHEDULE VERSUS A NEW ALGORITHM OF DOSE REDUCTIONS IN ELDERLY AND UNFIT NEWLY DIAGNOSED MULTIPLE MYELOMA PATIENTS RECEIVING LENALIDOMIDE PLUS STEROIDS
- Status
- COMPLETED
- Phase
- PHASE3
Lenalidomide and Combination Chemotherapy (DA-EPOCH-R) in Treating Patients With MYC-Associated B-Cell Lymphomas
- Status
- COMPLETED
- Phase
- PHASE1/PHASE2
Cyclophosphamide With Biochemical Progression During Lenalidomide-Dexamethasone Treatment for Relapsed/Refractory Multiple Myeloma (MM)
- Status
- COMPLETED
- Phase
- PHASE2
Ixazomib as a Replacement for Carfilzomib and Bortezomib for Multiple Myeloma Patients
- Status
- COMPLETED
- Phase
- PHASE1/PHASE2
Evaluation of the Safety and the Efficacy of Carfilzomib Combined With Cyclophosphamide and Dexamethasone (CCyd) or Lenalidomide and Dex (CRd) Followed by ASCT or 12 Cycles of Carf Combined With Dex and Len for Patients Eligible for ASCT With Newly Diagnosed Multiple Myeloma.
- Status
- COMPLETED
- Phase
- PHASE2
Study of Acalabrutinib Alone or in Combination Therapy in Subjects With B-cell Non-Hodgkin Lymphoma
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE1/PHASE2
Lenalidomide, Ibrutinib, and Rituximab in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma That Is Metastatic or Cannot Be Removed by Surgery
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE1
Study of Safety of Elotuzumab Administered Over Approximately 60 Minutes in Combination With Lenalidomide and Dexamethasone for Newly Diagnosed or Relapsed/Refractory Multiple Myeloma Patients
- Status
- COMPLETED
- Phase
- PHASE2
Continuous Lenalidomide Therapy Versus Observation Following Induction Without Lenalidomide, Pomalidomide or Thalidomide in Myeloma
- Status
- WITHDRAWN
- Phase
- PHASE3
Treatment Optimization in Patients With Untreated Multiple Myeloma
- Status
- TERMINATED
- Phase
- PHASE2/PHASE3
Ibrutinib and Lenalidomide With Dose Adjusted EPOCH-R in Subjects With Relapsed/Refractory Diffuse Large B-cell Lymphoma
- Status
- COMPLETED
- Phase
- PHASE1/PHASE2
Efficacy of Lenalidomide in Combination With Subcutaneous Rituximab + miniCHOP in DLBCL Patients of 80 y/o or+
- Status
- COMPLETED
- Phase
- PHASE3
Lenalidomide in Treating Patients With High Risk Acute Myeloid Leukemia in Remission
- Status
- COMPLETED
- Phase
- PHASE2
Lenalidomide vs Placebo Maintenance Therapy Following Melphalan Prednisone Velcade® Induction Therapy in NDMM
- Status
- COMPLETED
- Phase
- PHASE3
Brentuximab Vedotin and Lenalidomide for Relapsed or Refractory Diffuse Large B-cell Lymphoma
- Status
- COMPLETED
- Phase
- PHASE1
Sonidegib and Lenalidomide After Stem Cell Transplant in Treating Patients With Multiple Myeloma
- Status
- COMPLETED
- Phase
- PHASE2